Table 2. Prevalence of resistance to levofloxacin and pyrazinamide among new and previously treated isoniazid-resistant, rifampicin-susceptible TB (Hr-TB) cases.

	Azerbaijan	Bangladesh	Belarus (city of Minsk)	Pakistan	Philippines	South Africa (Gauteng)	South Africa (KwaZulu Natal)
Levofloxacin 1.5 mg/L
New	0/60, 0%	0/37, 0%	1/19, 5.3%	13/112, 11.6%	0/165, 0%	0/39, 0%	0/19, 0%
	(0%–6.0%)	(0%–9.5%)	(0.1%–26.0%)	(6.3%–19.0%)	(0%–2.2%)	(0%–9.0%)	(0%–17.6%)
Previously treated	2/44, 4.5%	0/10, 0%	1/2, 50%	4/14, 28.6%	0/29, 0%	0/10, 0%	0/14, 0%
	(0.6%–15.5%)	(0%–30.8%)	(1.3%–98.7%)	(8.4%–58.1%)	(0%–11.9%)	(0%–30.8%)	(0%–23.2%)
Pyrazinamide (pncA sequencing)
New	3/62, 4.8%	0/38, 0%	1/20, 5.0%	1/111, 0.9%	2/111, 1.8%	0/37, 0%	0/19, 0%
	(1.0%–13.5%)	(0%–9.3%)	(0.1%–24.9%)	(0%–4.9%)	(0.2%–6.4%)	(0%–9.5%)	(0%–17.6%)
Previously treated	3/43, 7.0%	0/10, 0%	1/3, 33.3%	0/13, 0%	1/9, 11.1%	0/10, 0%	0/14, 0%
	(1.5%–19.1%)	(0%–30.8%)	(0.8%–90.6%)	(0%–24.7%)	(0.3%–48.2%)	(0%–30.8%)	(0%–23.2%)
Any resistance to levofloxacin 1.5 mg/L or pyrazinamide (pncA sequencing)
New	3/60, 5.0%	0/37, 0%	1/19, 5.3%	14/111, 12.6%	2/110, 1.8%	0/35, 0%	0/19, 0%
	(1.0%–13.9%)	(0%–9.5%)	(0.1%–26.0%)	(7.0%–20.3%)	(0.2%–6.4%)	(0%–10.0%)	(0%–17.6%)
Previously treated	3/43, 7.0%	0/10, 0%	1/2, 50%	4/13, 30.8%	1/9, 11.1%	0/10, 0%	0/14, 0%
	(1.5%–19.1%)	(0%–30.8%)	(1.3%–98.7%)	(9.1%–61.4%)	(0.3%–48.2%)	(0%–30.8%)	(0%–23.2%)
Combined resistance to levofloxacin 1.5 mg/L and pyrazinamide (pncA sequencing)
New	0/60, 0%	0/37, 0%	1/19, 5.3%	0/111, 0%	0/110, 0%	0/35, 0%	0/19, 0%
	(0%–6.0%)	(0%–9.5%)	(0.1%–26.0%)	(0%–3.3%)	(0%–3.3%)	(0%–10.0%)	(0%–17.6%)
Previously treated	1/43, 2.3%	0/10, 0%	1/2, 50.0%	0/13, 0%	0/9, 0%	0/10, 0%	0/14, 0%
	(0.1%–12.3%)	(0%–30.8%)	(1.3%–98.7%)	(0%–24.7%)	(0%–33.6%)	(0%–30.8%)	(0%–23.2%)

Data shown are number of patients resistant divided by number tested, proportion resistant (%) (95% confidence interval).

Abbreviations: Hr-TB, isoniazid-resistant, rifampicin-susceptible TB; TB, tuberculosis